Glioblastoma, the most common and aggressive primary brain tumor, is highly invasive and neurologically destructive. The mean survival for glioblastoma patients is approximately 15 months and there is no effective therapy to significantly increase survival times to date. The development of effective therapy including mechanism-based therapies is urgently needed. At a molecular biology level, N6-methyladenine (m6A) mRNA modification is the most abundant posttranscriptional RNA modification in mammals. Recent studies have shown that m6A mRNA modifications affect cell survival, cell proliferation, invasion, and immune evasion of glioblastoma. In addition, m6A mRNA modifications are critical for glioblastoma stem cells, which could initiate the tumor and lead to therapy resistance. These findings implicate the function of m6A mRNA modification in tumorigenesis and progression, implicating its value in prognosis and therapies of human glioblastoma. This review focuses on the potential clinical significance of m6A mRNA modifications in prognostic and therapeutics of glioblastoma. With the identification of small-molecule compounds that activate or inhibit components of m6A mRNA modifications, a promising novel approach for glioblastoma therapy is emerging.
胶质母细胞瘤作为最常见且最具侵袭性的原发性脑肿瘤，具有高度浸润性和神经破坏性。患者中位生存期约为15个月，目前尚无能显著延长生存期的有效疗法。亟需开发包括基于作用机制疗法在内的有效治疗方案。在分子生物学层面，N6-甲基腺嘌呤（m6A）mRNA修饰是哺乳动物中最丰富的转录后RNA修饰方式。最新研究表明，m6A mRNA修饰影响胶质母细胞瘤的细胞存活、增殖、侵袭及免疫逃逸能力。此外，m6A mRNA修饰对胶质母细胞瘤干细胞至关重要，这类细胞可诱发肿瘤并导致治疗抵抗。这些发现揭示了m6A mRNA修饰在肿瘤发生发展中的关键作用，预示其在胶质母细胞瘤预后评估与治疗中的潜在价值。本综述聚焦m6A mRNA修饰在胶质母细胞瘤预后判断与治疗策略中的临床意义。随着调控m6A mRNA修饰组分的小分子化合物的发现，一种前景广阔的胶质母细胞瘤治疗新策略正在形成。
m6A mRNA Modifications in Glioblastoma: Emerging Prognostic Biomarkers and Therapeutic Targets
肿瘤(癌症)患者之家